Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue

Figures & data

Table 1 Demographic data of per protocol set

Previous PGA	Travoprost	Latanoprost	Tafluprost	Bimatoprost
Sex, n
Male, n	23	18	10	3
Female, n	47	27	19	10
N	70	45	29	13
Age, year
Mean ± SD	66.0±11.6	67.0±1.0	68.6±11.6	64.2±11.1
Range	39–88	40–83	42–88	43–84
N	70	45	29	13
Baseline IOP, mmHg
Mean ± SD	16.1±2.6	15.6±2.9	17.5±3.2	17.2±5.1
Range	10–22.5	9.5–22	11–22.5	10.5–27.5
N	52	26	21	10
Corneal thickness, μm
Mean ± SD	522.0±33.3	527.0±34.0	527.0±35.9	530.0±34.4
Range	434.0–590.0	454.0–584.0	476.0–629.0	472.0–568.0
N	66	43	27	13
MD, dB
Mean ± SD	−4.54±4.57	−4.84±4.88	−5.25±5.81	−5.08±4.36
Range	−14.94 to 2.54	−16.06 to 1.79	−19.49 to 1.53	−14.73 to −0.62
N	66	43	27	13
PSD, dB
Mean ± SD	6.19±4.18	6.86±4.67	6.18±4.69	5.64±3.55
Range	1.15–14.56	1.25–16.68	1.15–14.93	1.72–11.79

Abbreviations: IOP, intraocular pressure; MD, mean deviation; PSD, pattern standard deviation; SD, standard deviation.

Table 2 Least-squares mean of IOP changes from baseline at 12 weeks (mmHg)

	LSM	95% CI	P-value
Travoprost, n=70	−1.4	−1.9 to −0.9	<0.0001
Latanoprost, n=45	−1.8	−2.5 to −1.1	<0.0001
Tafluprost, n=29	−3.5	−4.3 to −2.7	<0.0001
Bimatoprost, n=13	−0.5	−1.7 to 0.6	0.3720

Note: Least squares means and confidence intervals were based on a multiple linear model.

Abbreviations: CI, confidence interval; IOP, intraocular pressure; LSM, least squares mean.

Table 3 Summary of measured IOP

Visit	Baseline	4 weeks	8 weeks	12 weeks
IOP (mmHg)
Travoprost, n=70
Mean ± SD	16.1±2.6	14.7±3.3	14.8±3.3	14.7±3.1
Range	10–22.5	9–26	8–26	8–26
Latanoprost, n=45
Mean ± SD	15.6±2.9	14.2±2.6	13.8±2.7	14.2±2.6
Range	9.5–22	8–19	8–20	9–20
Tafluprost, n=29
Mean ± SD	17.5±3.2	14.4±2.9	14.5±2.9	13.9±2.8
Range	11–22.5	9–21.25	8–20	9–20
Bimatoprost, n=13
Mean ± SD	17.2±5.1	15.4±4.1	17.5±5.0	16.5±5.2
Range	10.5–27.5	9–22.5	11–26	11–28

Abbreviations: IOP, intraocular pressure; SD, standard deviation.

Table 4 Superficial punctate keratopathy scores and conjunctival hyperemia scores

Visit	Baseline	4 weeks	8 weeks	12 weeks
Superficial punctate keratopathy scores
Travoprost, n=69
Mean	0.58	0.80	0.65	0.85
SD	1.40	1.41	1.25	1.43
Latanoprost, n=45
Mean	0.27	0.62	0.67	0.49
SD	0.58	1.25	1.43	1.16
Tafluprost, n=29
Mean	1.24	1.55	1.69	1.72
SD	1.84	2.63	3.02	2.89
Bimatoprost, n=13
Mean	0.23	1.00	1.08	1.00
SD	0.60	1.35	1.12	1.29
Conjunctival hyperemia scores
Travoprost, n=70
Mean	0.46	0.49	0.44	0.44
SD	0.67	0.65	0.61	0.63
Latanoprost, n=45
Mean	0.29	0.51	0.44	0.49
SD	0.51	0.73	0.59	0.55
Tafluprost, n=29
Mean	0.38	0.59	0.48	0.62
SD	0.62	0.73	0.69	0.73
Bimatoprost, n=13
Mean	0.69	0.62	0.38	0.46
SD	0.85	0.77	0.65	0.66

Abbreviation: SD, standard deviation.

Table 5 Adverse events related to the study drug

	Travoprost, n=73	Latanoprost, n=48	Tafluprost, n=31	Bimatoprost, n=14
Type (n)
Eye disorders
Deepening of eye lid sulcus	1	3	4
Growth of eyelashes		2	3
Blepharal pigmentation		4
Superficial punctate keratopathy	2	1	1
Dry eyes	1		2
Foreign body sensation in eyes			2
Eyelid ptosis			1
Eye irritation			1	1
Eye pruritus	1		1
Iritis			1
Keratitis			1
Vision blurred	1
Visual acuity reduced		1
Conjunctival hyperemia		1
Corneal epitheliopathy	1
Other
Blood pressure increased				1
Headache		1
Herpes zoster			1
Itchy skin		1
Rash				1
No of events	7	14	18	3